U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C11H20N2O2
Molecular Weight 212.2891
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BRIVARACETAM

SMILES

CCC[C@]1([H])CC(=O)N(C1)[C@@]([H])(CC)C(=N)O

InChI

InChIKey=MSYKRHVOOPPJKU-BDAKNGLRSA-N
InChI=1S/C11H20N2O2/c1-3-5-8-6-10(14)13(7-8)9(4-2)11(12)15/h8-9H,3-7H2,1-2H3,(H2,12,15)/t8-,9+/m1/s1

HIDE SMILES / InChI

Molecular Formula C11H20N2O2
Molecular Weight 212.2891
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Brivaracetam (UCB 34714, trade name Briviact), the 4-n-propyl analog of levetiracetam, is a racetam derivative with anticonvulsant properties. Briviact is indicated as adjunctive therapy in the treatment of partial-onset seizures in patients 16 years of age and older with epilepsy. Brivaracetam is believed to act by binding to the ubiquitous synaptic vesicle glycoprotein 2A (SV2A), like levetiracetam, but with 20-fold greater affinity. There is some evidence that racetams including levetiracetam and brivaracetam access the luminal side of recycling synaptic vesicles during vesicular endocytosis. They may reduce excitatory neurotransmitter release and enhance synaptic depression during trains of high-frequency activity, such as is believed to occur during epileptic activity.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
BRIVIACT

Approved Use

BRIVIACT is indicated as adjunctive therapy in the treatment of partial-onset seizures in patients 16 years of age and older with epilepsy

Launch Date

1.46301125E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
3.5 μg/mL
200 mg 1 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
BRIVARACETAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
7.7 μg/mL
400 mg 1 times / day multiple, oral
dose: 400 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
BRIVARACETAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
13.3 μg/mL
800 mg 1 times / day multiple, oral
dose: 800 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
BRIVARACETAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
9 μg/mL
800 mg single, oral
dose: 800 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BRIVARACETAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
2.2 μg/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BRIVARACETAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
4.7 μg/mL
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BRIVARACETAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
28 μg × h/mL
200 mg 1 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
BRIVARACETAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
55.4 μg × h/mL
400 mg 1 times / day multiple, oral
dose: 400 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
BRIVARACETAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
90.8 μg × h/mL
800 mg 1 times / day multiple, oral
dose: 800 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
BRIVARACETAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
104.1 μg × h/mL
800 mg single, oral
dose: 800 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BRIVARACETAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
27.5 μg × h/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BRIVARACETAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
56 μg × h/mL
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BRIVARACETAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
7.3 h
200 mg 1 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
BRIVARACETAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
6.8 h
400 mg 1 times / day multiple, oral
dose: 400 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
BRIVARACETAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
6.3 h
800 mg 1 times / day multiple, oral
dose: 800 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
BRIVARACETAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
7.8 h
800 mg single, oral
dose: 800 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BRIVARACETAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
7.7 h
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BRIVARACETAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
7.3 h
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BRIVARACETAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
80%
unknown, unknown
BRIVARACETAM plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
1400 mg single, oral
Highest studied dose|MID
Dose: 1400 mg
Route: oral
Route: single
Dose: 1400 mg
Sources:
healthy, 18-55 years
n = 6
Health Status: healthy
Age Group: 18-55 years
Sex: M
Population Size: 6
Sources:
Other AEs: Somnolence, Blurred vision...
Other AEs:
Somnolence (severe, 2 patients)
Blurred vision (1 patient)
Dizziness (2 patients)
Agitation (1 patient)
Bradyphrenia (1 patient)
Disorientation (1 patient)
Euphoric mood (1 patient)
Sources:
1000 mg single, oral
MTD
Dose: 1000 mg
Route: oral
Route: single
Dose: 1000 mg
Sources:
healthy, 18-55 years
n = 6
Health Status: healthy
Age Group: 18-55 years
Sex: M
Population Size: 6
Sources:
Other AEs: Somnolence, Blurred vision...
Other AEs:
Somnolence (2 patients)
Blurred vision (1 patient)
Dizziness (3 patients)
Agitation (1 patient)
Bradyphrenia (1 patient)
Disorientation (1 patient)
Euphoric mood (1 patient)
Sources:
200 mg 1 times / day steady, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 37.2 years
n = 2186
Health Status: unhealthy
Age Group: 37.2 years
Sex: M+F
Population Size: 2186
Sources:
Disc. AE: Convulsion, Somnolence...
AEs leading to
discontinuation/dose reduction:
Convulsion (1.4%)
Somnolence (0.7%)
Depression (0.6%)
Dizziness (0.6%)
Fatigue (0.5%)
Suicidal ideation (0.5%)
Suicide attempt (0.5%)
Sources:
800 mg 1 times / day steady, oral
Highest studied dose
Dose: 800 mg, 1 times / day
Route: oral
Route: steady
Dose: 800 mg, 1 times / day
Sources: Page: p. 28
healthy, 64.1 years
n = 7
Health Status: healthy
Age Group: 64.1 years
Population Size: 7
Sources: Page: p. 28
Other AEs: Somnolence, Dizziness...
2 mg/kg 2 times / day steady, oral
Highest studied dose
Dose: 2 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 2 mg/kg, 2 times / day
Sources:
unhealthy, <8 years
Health Status: unhealthy
Condition: generalized epilepsy
Age Group: <8 years
Sex: M+F
Sources:
AEs

AEs

AESignificanceDosePopulation
Agitation 1 patient
1400 mg single, oral
Highest studied dose|MID
Dose: 1400 mg
Route: oral
Route: single
Dose: 1400 mg
Sources:
healthy, 18-55 years
n = 6
Health Status: healthy
Age Group: 18-55 years
Sex: M
Population Size: 6
Sources:
Blurred vision 1 patient
1400 mg single, oral
Highest studied dose|MID
Dose: 1400 mg
Route: oral
Route: single
Dose: 1400 mg
Sources:
healthy, 18-55 years
n = 6
Health Status: healthy
Age Group: 18-55 years
Sex: M
Population Size: 6
Sources:
Bradyphrenia 1 patient
1400 mg single, oral
Highest studied dose|MID
Dose: 1400 mg
Route: oral
Route: single
Dose: 1400 mg
Sources:
healthy, 18-55 years
n = 6
Health Status: healthy
Age Group: 18-55 years
Sex: M
Population Size: 6
Sources:
Disorientation 1 patient
1400 mg single, oral
Highest studied dose|MID
Dose: 1400 mg
Route: oral
Route: single
Dose: 1400 mg
Sources:
healthy, 18-55 years
n = 6
Health Status: healthy
Age Group: 18-55 years
Sex: M
Population Size: 6
Sources:
Euphoric mood 1 patient
1400 mg single, oral
Highest studied dose|MID
Dose: 1400 mg
Route: oral
Route: single
Dose: 1400 mg
Sources:
healthy, 18-55 years
n = 6
Health Status: healthy
Age Group: 18-55 years
Sex: M
Population Size: 6
Sources:
Dizziness 2 patients
1400 mg single, oral
Highest studied dose|MID
Dose: 1400 mg
Route: oral
Route: single
Dose: 1400 mg
Sources:
healthy, 18-55 years
n = 6
Health Status: healthy
Age Group: 18-55 years
Sex: M
Population Size: 6
Sources:
Somnolence severe, 2 patients
1400 mg single, oral
Highest studied dose|MID
Dose: 1400 mg
Route: oral
Route: single
Dose: 1400 mg
Sources:
healthy, 18-55 years
n = 6
Health Status: healthy
Age Group: 18-55 years
Sex: M
Population Size: 6
Sources:
Agitation 1 patient
1000 mg single, oral
MTD
Dose: 1000 mg
Route: oral
Route: single
Dose: 1000 mg
Sources:
healthy, 18-55 years
n = 6
Health Status: healthy
Age Group: 18-55 years
Sex: M
Population Size: 6
Sources:
Blurred vision 1 patient
1000 mg single, oral
MTD
Dose: 1000 mg
Route: oral
Route: single
Dose: 1000 mg
Sources:
healthy, 18-55 years
n = 6
Health Status: healthy
Age Group: 18-55 years
Sex: M
Population Size: 6
Sources:
Bradyphrenia 1 patient
1000 mg single, oral
MTD
Dose: 1000 mg
Route: oral
Route: single
Dose: 1000 mg
Sources:
healthy, 18-55 years
n = 6
Health Status: healthy
Age Group: 18-55 years
Sex: M
Population Size: 6
Sources:
Disorientation 1 patient
1000 mg single, oral
MTD
Dose: 1000 mg
Route: oral
Route: single
Dose: 1000 mg
Sources:
healthy, 18-55 years
n = 6
Health Status: healthy
Age Group: 18-55 years
Sex: M
Population Size: 6
Sources:
Euphoric mood 1 patient
1000 mg single, oral
MTD
Dose: 1000 mg
Route: oral
Route: single
Dose: 1000 mg
Sources:
healthy, 18-55 years
n = 6
Health Status: healthy
Age Group: 18-55 years
Sex: M
Population Size: 6
Sources:
Somnolence 2 patients
1000 mg single, oral
MTD
Dose: 1000 mg
Route: oral
Route: single
Dose: 1000 mg
Sources:
healthy, 18-55 years
n = 6
Health Status: healthy
Age Group: 18-55 years
Sex: M
Population Size: 6
Sources:
Dizziness 3 patients
1000 mg single, oral
MTD
Dose: 1000 mg
Route: oral
Route: single
Dose: 1000 mg
Sources:
healthy, 18-55 years
n = 6
Health Status: healthy
Age Group: 18-55 years
Sex: M
Population Size: 6
Sources:
Fatigue 0.5%
Disc. AE
200 mg 1 times / day steady, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 37.2 years
n = 2186
Health Status: unhealthy
Age Group: 37.2 years
Sex: M+F
Population Size: 2186
Sources:
Suicidal ideation 0.5%
Disc. AE
200 mg 1 times / day steady, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 37.2 years
n = 2186
Health Status: unhealthy
Age Group: 37.2 years
Sex: M+F
Population Size: 2186
Sources:
Suicide attempt 0.5%
Disc. AE
200 mg 1 times / day steady, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 37.2 years
n = 2186
Health Status: unhealthy
Age Group: 37.2 years
Sex: M+F
Population Size: 2186
Sources:
Depression 0.6%
Disc. AE
200 mg 1 times / day steady, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 37.2 years
n = 2186
Health Status: unhealthy
Age Group: 37.2 years
Sex: M+F
Population Size: 2186
Sources:
Dizziness 0.6%
Disc. AE
200 mg 1 times / day steady, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 37.2 years
n = 2186
Health Status: unhealthy
Age Group: 37.2 years
Sex: M+F
Population Size: 2186
Sources:
Somnolence 0.7%
Disc. AE
200 mg 1 times / day steady, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 37.2 years
n = 2186
Health Status: unhealthy
Age Group: 37.2 years
Sex: M+F
Population Size: 2186
Sources:
Convulsion 1.4%
Disc. AE
200 mg 1 times / day steady, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 37.2 years
n = 2186
Health Status: unhealthy
Age Group: 37.2 years
Sex: M+F
Population Size: 2186
Sources:
Dizziness 42.9%
800 mg 1 times / day steady, oral
Highest studied dose
Dose: 800 mg, 1 times / day
Route: oral
Route: steady
Dose: 800 mg, 1 times / day
Sources: Page: p. 28
healthy, 64.1 years
n = 7
Health Status: healthy
Age Group: 64.1 years
Population Size: 7
Sources: Page: p. 28
Somnolence 57.1%
800 mg 1 times / day steady, oral
Highest studied dose
Dose: 800 mg, 1 times / day
Route: oral
Route: steady
Dose: 800 mg, 1 times / day
Sources: Page: p. 28
healthy, 64.1 years
n = 7
Health Status: healthy
Age Group: 64.1 years
Population Size: 7
Sources: Page: p. 28
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no [IC50 541 uM]
no [IC50 740 uM]
no [Inhibition 200 uM]
no [Inhibition 650 uM]
no [Inhibition 650 uM]
no [Inhibition 650 uM]
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
Drug as victimTox targets
PubMed

PubMed

TitleDatePubMed
Antiepileptic drug discovery: lessons from the past and future challenges.
2005
Gateways to clinical trials.
2005 Jan-Feb
Brivaracetam UCB.
2005 Jul
New antiepileptic drugs that are second generation to existing antiepileptic drugs.
2006 Jun
Diverse mechanisms of antiepileptic drugs in the development pipeline.
2006 Jun
Gateways to clinical trials.
2007 Dec
Pharmacological management of epilepsy: recent advances and future prospects.
2008
Gateways to clinical trials.
2008 Apr
Treatment of Lennox-Gastaut syndrome: overview and recent findings.
2008 Dec
New molecular targets for antiepileptic drugs: alpha(2)delta, SV2A, and K(v)7/KCNQ/M potassium channels.
2008 Jul
Gateways to clinical trials.
2008 Mar
SVOP is a nucleotide binding protein.
2009
Brivaracetam inhibits spreading depression in rat neocortical slices in vitro.
2009 Jul
Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions.
2009 Mar-Apr
Adjunctive brivaracetam for refractory partial-onset seizures: a randomized, controlled trial.
2010 Aug 10
New drugs for pediatric epilepsy.
2010 Dec
Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders.
2010 Feb 12
Physiologically based pharmacokinetic/pharmacodynamic animal-to-man prediction of therapeutic dose in a model of epilepsy.
2010 Mar
Patents

Sample Use Guides

The recommended starting dosage is 50 mg twice daily (100 mg per day). Based on individual patient tolerability and therapeutic response, the dosage may be adjusted down to 25 mg twice daily (50 mg per day) or up to 100 mg twice daily (200 mg per day). BRIVIACT (brivaracetam) injection may be used when oral administration is temporarily not feasible. BRIVIACT injection should be administered at the same dosage and same frequency as BRIVIACT tablets and oral solution.
Route of Administration: Other
Brivaracetam (BRV) is able to modulate the voltage-activated Na(+) inflow in cortical neurons. Voltage-activated Na(+) currents were recorded by whole-cell patch-clamp on neuronal somas of rat neocortical neurons, grown in dissociated cell culture for up to 12 days. BRV, dissolved at the desired final concentration (between 0.2 microM and 1 mM) was applied by a multi-barrel pipette system near the soma of the recorded neuron. BRV produced a concentration-dependent inhibition of voltage-dependent Na(+) currents with IC(50) values of 41 microM at the holding potential of -100 mV, and of 6.5 microM at the holding potential of -60 mV. The voltage-dependence of activation and the kinetics of fast inactivation were not modified in the presence of BRV (30 microM).
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:35:16 UTC 2021
Edited
by admin
on Fri Jun 25 21:35:16 UTC 2021
Record UNII
U863JGG2IA
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BRIVARACETAM
DASH   INN   MART.   MI   USAN   WHO-DD  
USAN   INN  
Official Name English
BRIVARACETAM [MART.]
Common Name English
BRIVARACETAM [INN]
Common Name English
BRIVARACETAM [USAN]
Common Name English
BRIVARACETAM [WHO-DD]
Common Name English
BRIVARACETAM [MI]
Common Name English
UCB 34714
Code English
BRIVIACT
Brand Name English
UCB-34714
Code English
(2S)-2-((4R)-2-OXO-4-PROPYLPYRROLIDIN-1-YL)BUTANAMIDE
Systematic Name English
(2S)-2-((4R)-2-OXO-4-PROPYLTETRAHYDRO-1H-PYRROL-1-YL) BUTANAMIDE
Systematic Name English
1-PYRROLIDINEACETAMIDE, .ALPHA.-ETHYL-2-OXO-4-PROPYL (.ALPHA.S,4R)-
Common Name English
BRIVARACETAM [ORANGE BOOK]
Common Name English
Classification Tree Code System Code
EU-Orphan Drug EU/3/05/315
Created by admin on Fri Jun 25 21:35:16 UTC 2021 , Edited by admin on Fri Jun 25 21:35:16 UTC 2021
WHO-ATC N03AX23
Created by admin on Fri Jun 25 21:35:16 UTC 2021 , Edited by admin on Fri Jun 25 21:35:16 UTC 2021
FDA ORPHAN DRUG 207305
Created by admin on Fri Jun 25 21:35:16 UTC 2021 , Edited by admin on Fri Jun 25 21:35:16 UTC 2021
FDA ORPHAN DRUG 724019
Created by admin on Fri Jun 25 21:35:16 UTC 2021 , Edited by admin on Fri Jun 25 21:35:16 UTC 2021
FDA ORPHAN DRUG 711119
Created by admin on Fri Jun 25 21:35:16 UTC 2021 , Edited by admin on Fri Jun 25 21:35:16 UTC 2021
Code System Code Type Description
WIKIPEDIA
BRIVARACETAM
Created by admin on Fri Jun 25 21:35:16 UTC 2021 , Edited by admin on Fri Jun 25 21:35:16 UTC 2021
PRIMARY
DRUG CENTRAL
5068
Created by admin on Fri Jun 25 21:35:16 UTC 2021 , Edited by admin on Fri Jun 25 21:35:16 UTC 2021
PRIMARY
PUBCHEM
9837243
Created by admin on Fri Jun 25 21:35:16 UTC 2021 , Edited by admin on Fri Jun 25 21:35:16 UTC 2021
PRIMARY
ChEMBL
CHEMBL607400
Created by admin on Fri Jun 25 21:35:16 UTC 2021 , Edited by admin on Fri Jun 25 21:35:16 UTC 2021
PRIMARY
INN
8642
Created by admin on Fri Jun 25 21:35:16 UTC 2021 , Edited by admin on Fri Jun 25 21:35:16 UTC 2021
PRIMARY
NDF-RT
N0000192345
Created by admin on Fri Jun 25 21:35:16 UTC 2021 , Edited by admin on Fri Jun 25 21:35:16 UTC 2021
PRIMARY Epoxide Hydrolase Inhibitors [MoA]
NCI_THESAURUS
C65270
Created by admin on Fri Jun 25 21:35:16 UTC 2021 , Edited by admin on Fri Jun 25 21:35:16 UTC 2021
PRIMARY
EVMPD
SUB25397
Created by admin on Fri Jun 25 21:35:16 UTC 2021 , Edited by admin on Fri Jun 25 21:35:16 UTC 2021
PRIMARY
DRUG BANK
DB05541
Created by admin on Fri Jun 25 21:35:16 UTC 2021 , Edited by admin on Fri Jun 25 21:35:16 UTC 2021
PRIMARY
LACTMED
Brivaracetam
Created by admin on Fri Jun 25 21:35:16 UTC 2021 , Edited by admin on Fri Jun 25 21:35:16 UTC 2021
PRIMARY
RXCUI
1739745
Created by admin on Fri Jun 25 21:35:16 UTC 2021 , Edited by admin on Fri Jun 25 21:35:16 UTC 2021
PRIMARY
FDA UNII
U863JGG2IA
Created by admin on Fri Jun 25 21:35:16 UTC 2021 , Edited by admin on Fri Jun 25 21:35:16 UTC 2021
PRIMARY
CAS
357336-20-0
Created by admin on Fri Jun 25 21:35:16 UTC 2021 , Edited by admin on Fri Jun 25 21:35:16 UTC 2021
PRIMARY
MERCK INDEX
M2654
Created by admin on Fri Jun 25 21:35:16 UTC 2021 , Edited by admin on Fri Jun 25 21:35:16 UTC 2021
PRIMARY Merck Index
Related Record Type Details
METABOLIC ENZYME -> SUBSTRATE
MAJOR
METABOLIC ENZYME -> SUBSTRATE
EXCRETED UNCHANGED
AMOUNT EXCRETED
URINE
BINDER->LIGAND
BINDING
TARGET->LIGAND
Related Record Type Details
METABOLITE INACTIVE -> PARENT
AMOUNT EXCRETED
URINE
METABOLITE INACTIVE -> PARENT
MAJOR
PLASMA
METABOLITE INACTIVE -> PARENT
AMOUNT EXCRETED
URINE
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Tmax PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC